Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

CorMedix (CRMD) Shares Outstanding (2016 - 2025)

CorMedix has reported Shares Outstanding over the past 16 years, most recently at $79.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $79.3 million for Q4 2025, up 122954.55% from a year ago — trailing twelve months through Dec 2025 was $79.3 million (up 122954.55% YoY), and the annual figure for FY2025 was $79.3 million, up 122954.55%.
  • Shares Outstanding reached $79.3 million in Q4 2025 per CRMD's latest filing, up from $78.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $79.3 million in Q4 2025 and bottomed at $182.0 in Q4 2023.
  • Median Shares Outstanding over the past 5 years was $38.1 million (2021), compared with a mean of $33.1 million.
  • The largest annual shift saw Shares Outstanding crashed 100.0% in 2023 before it surged 122954.55% in 2025.
  • Over 5 years, Shares Outstanding stood at $181622.0 in 2021, then surged by 23473.79% to $42.8 million in 2022, then plummeted by 100.0% to $182.0 in 2023, then skyrocketed by 35290.66% to $64411.0 in 2024, then soared by 122954.55% to $79.3 million in 2025.
  • Business Quant data shows Shares Outstanding for CRMD at $79.3 million in Q4 2025, $78.3 million in Q3 2025, and $91623.0 in Q2 2025.